A study describing persistence of DTG-containing 2DR and three-drug-regimens (3DR) in people living with HIV from real-life cohort data
Latest Information Update: 27 Jan 2020
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary) ; Dolutegravir/emtricitabine/tenofovir-alafenamide (Primary) ; Dolutegravir/lamivudine (Primary) ; Dolutegravir/rilpivirine (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 27 Jan 2020 New trial record